https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22946 Wed 11 Apr 2018 16:42:13 AEST ]]> Adjuvant exemestane with ovarian suppression in premenopausal breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16287 Wed 11 Apr 2018 11:53:01 AEST ]]> Are SOFT and TEXT results practice changing and how? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50025 Tue 27 Jun 2023 16:47:40 AEST ]]> Adjuvant ovarian function suppression and cognitive function in women with breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24211 Thu 28 Oct 2021 13:03:31 AEDT ]]> Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25887 Thu 21 Jul 2022 15:37:04 AEST ]]>